TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04322136

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pleurodesis via Video-assisted thoracoscopic surgery
Description: Video-assisted thoracoscopic surgery is a type of key-hole surgery performed under general anaesthetic and usually single lung ventilation by a cardio-thoracic surgeon. This is expected to take about 1 hour. Between one and three ports are used to insert a camera and instruments into the chest cavity. Adhesions can be broken down if present and the lining of the lung (visceral pleura) can sometimes be removed (decortication) to facilitate lung re-expansion. The surgeon can then perform either mechanical abrasion or talc poudrage to induce inflammation and subsequent pleurodesis. A chest drain is left in situ post-operatively and is removed when the fluid draining is below a certain volume depending on local practice.

Intervention type: DEVICE
Group type: OTHER
Intervention: Indwelling pleural catheter (with talc pleurodesis if suitable)
Description: Once the indwelling pleural catheter is inserted, the pleural fluid will be evacuated as completely as possible. If the lung fully re-expands, 4-5g of sterile graded talc will be instilled via the IPC. The participant will then be discharged on a daily drainage regimen for 14 days. At review in clinic on day 14, the participant will be assessed for spontaneous pleurodesis (\<50ml drainage on 3 consecutive drainage attempts). If pleurodesis has occurred and there is no residual symptomatic effusion, arrangements will be made for IPC removal. Otherwise the participant will switch to a symptom-guided drainage regimen. If the lung does not fully re-expand following complete fluid evacuation, they will be discharged on a symptom-guided regimen without instillation of talc. The drainage regimen will continue for the duration of the study and beyond if pleurodesis has not occurred and pleural fluid continues to accumulate.
Study: NCT01145482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: 20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
Study: NCT02417025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE
Description: Prolonged Exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PE
Description: Prolonged Exposure
Study: NCT03599596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
Study: NCT01762488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the renal arteries
Description: Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal angiography
Description: Renal angiography by femoral access
Study: NCT03320356

Intervention type: OTHER
Intervention: the French version of the Oxford Shoulder Score
Study: NCT03159143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m\^2
Study: NCT03830021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt reduction program
Description: Dietary and behavioural change program, led by nutritionists, including low sodium dietary advice; use of aromatic herbs and spices in food instead of salt; motivational activities; food diaries; restrict salty processed foods; eat more fresh foods and seasoning advice; problem solving exercises; digital bulletins; individual counselling reinforced at each clinic visit and shopping counselling at local supermarket.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle program
Description: Participants receive an educational healthy lifestyle program that includes 1) methods to cook healthier and the Mediterranean diet based on a high intake of fresh fruit and, vegetables, beans, grain legumes, lentils, nuts, cereals, and olive oil as source of fat; moderate intake of fish, poultry, yoghurt and cheese, low intake of salt, red meat, processed meats and sugar; 2) physical activity; 3) drink more water and reducing alcohol consumption; and 4) sleep education.
Study: NCT04333693

Intervention type: PROCEDURE
Intervention: Vascular surgery
Description: Open vascular, endovascular or hybrid procedures
Study: NCT00872547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy ASR™ Hip System
Description: Resurfacing system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy ASR™ XL Head / ASR™ Acetabular Cup System
Description: Large Metal-on-Metal Total Hip Replacement
Study: NCT02347709

Intervention type: PROCEDURE
Intervention: Diabetic Foot Ulcer Biopsy
Description: Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.

Intervention type: OTHER
Intervention: Survey
Description: Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.

Intervention type: OTHER
Intervention: Survey
Description: Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.

Intervention type: OTHER
Intervention: Survey
Description: Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.

Intervention type: OTHER
Intervention: Comprehensive Neuropathy Assessment
Description: Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.

Intervention type: OTHER
Intervention: Comprehensive Neuropathy Assessment
Description: Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.

Intervention type: OTHER
Intervention: Comprehensive Neuropathy Assessment
Description: Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.

Intervention type: OTHER
Intervention: Wound Photography
Description: Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
Study: NCT06609993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue ephedrine administration
Description: ephedrine (Ephedrinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 10 mg will be administered intravenously when DAP \< 50 mmHg or MAP \< 65 mmHg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: concentrate of red blood cells
Description: concentrate of red blood cells will be transfused when concentration of haemoglobin \< 10g%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: concentrate of red blood cells
Description: concentrate of red blood cells will be transfused when concentration of haemoglobin \< 10g%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: concentrate of red blood cells
Description: concentrate of red blood cells will be transfused when concentration of haemoglobin \< 10g%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: red blood cells autotransfusion
Description: red blood cells from the operation site will be retransfused using cell saver
Study: NCT00533338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Gain Prevention Program
Description: Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Packet of questionnaires will be completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Packet of questionnaires will be completed.
Study: NCT06609993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: red blood cells autotransfusion
Description: red blood cells from the operation site will be retransfused using cell saver

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: red blood cells autotransfusion
Description: red blood cells from the operation site will be retransfused using cell saver

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primary treatment of postoperative nausea and vomiting (PONV)
Description: dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously when incidence of PONV is observed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primary treatment of postoperative nausea and vomiting (PONV)
Description: dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously when incidence of PONV is observed
Study: NCT01235377

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Favor one of two thiazides for new prescriptions & attempt target dose
Description: Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Favor one of two thiazides for new prescriptions & attempt target dose
Description: Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
Study: NCT02466399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLAT-001
Description: Subconjunctival injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Description: Latanoprost ophthalmic solution q.d., evening
Study: NCT02686996

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carnosine
Description: Carnosine capsules (2g) twice per day for 14 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
Study: NCT01554124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 40 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age).~Treatment duration = 21 ± 7 days
Study: NCT00581217

Intervention type: OTHER
Intervention: Aquacel Ag
Description: Aquacel Ag will be applied to one donor site.

Intervention type: OTHER
Intervention: Glucan II
Description: Glucan II to be applied to a donor site on same patient for comparison
Study: NCT01799941

Intervention type: DRUG
Group type: OTHER
Intervention: Nuedexta (DM 20 mg/Q 10 mg)
Description: Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
Study: NCT03953742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-200
Description: CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
Study: NCT01563939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg.
Study: NCT03347591

Intervention type: GENETIC
Intervention: WES
Description: 136 bleeding related OMIM (Online Mendelian Inheritance in Man)-proved genes involved in haemostasis will be selected from Whole Exome Sequencing (WES)

Intervention type: DIAGNOSTIC_TEST
Intervention: Several assays
Description: Patients will be approached by their own treating physician. Data will be collected through questionnaires, a clinical interview, a blood and saliva sample obtained from each participant, and thorough review of electronic patient records. All procedures are study related. In case a physician visit with the treating physician is already planned, or in case a venepuncture for regular diagnostics or treatment is already planned, this can be combined with the study procedures to prevent an extra visit.
Study: NCT01620424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
Study: NCT03496740

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penile Block
Description: Ultrasound guided dorsal penile nerve block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Block
Description: Nerve stimulation guided bilateral pudendal block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Block Drug)
Description: Block drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Block Drug)
Description: Block drug
Study: NCT01712282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity, 2 x 30 minutes/day
Description: weight-bearing treadmill, pulse reserve increase of 50%
Study: NCT02650739

Intervention type: PROCEDURE
Intervention: Macular hole surgery
Description: Vitrectomy with internal limiting membrane removal and gas tamponade

Intervention type: PROCEDURE
Intervention: Macular hole surgery
Description: Vitrectomy with internal limiting membrane removal and gas tamponade
Study: NCT03587636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposome bupivacaine
Description: interscalene block with liposomal bupivacaine plus bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: interscalene block with bupivacaine
Study: NCT01655875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
Study: NCT06609993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primary treatment of postoperative nausea and vomiting (PONV)
Description: dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously when incidence of PONV is observed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secondary treatment of postoperative nausea and vomiting (PONV)
Description: Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously when incidence of persistent PONV is observed despite the dexamethasone in a dose of 4 mg will be administration intravenously
Study: NCT02008656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OXAL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OXAL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda®)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiotherapy (IMRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity modulated radiotherapy (IMRT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DRE-Endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DRE-Endoscopy
Study: NCT00667264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perineural ropivacaine
Description: Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: perineural ropivacaine
Description: Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
Study: NCT00723827

Intervention type: DRUG
Intervention: Temozolomide
Description: Administration of temozolomide based on the product labeling.

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
Study: NCT00839124

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Center Reference Endotoxin (CCRE)
Description: inhalation challenge with 20,000 EU CCRE

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Center Reference Endotoxin (CCRE)
Description: inhalation of 20,000 EU CCRE
Study: NCT01429090

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood sampling
Description: blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vagantin®
Description: administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methantheline solution
Description: administration 100 ml methantheline solution (100 mg methantheline bromide)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of salivation
Description: Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of salivation
Description: Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of accommodation
Description: Accommodation was measured with the optometer according to Schober (Velhagen 1972)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of accommodation
Description: Accommodation was measured with the optometer according to Schober (Velhagen 1972)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pupillometry
Description: Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli